SI-BONE FY2025 EPS Forecast Decreased by Cantor Fitzgerald

SI-BONE, Inc. (NASDAQ:SIBN) – Equities research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of SI-BONE in a research note issued to investors on Tuesday, February 25th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($0.64) per share for the year, down from their prior estimate of ($0.19). Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for SI-BONE’s current full-year earnings is ($0.78) per share.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The company had revenue of $49.00 million during the quarter, compared to analyst estimates of $48.87 million.

SIBN has been the subject of a number of other reports. Truist Financial restated a “buy” rating and issued a $22.00 target price (up from $18.00) on shares of SI-BONE in a research note on Tuesday. Needham & Company LLC raised their target price on SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $24.50.

SI-BONE Stock Down 1.6 %

Shares of NASDAQ:SIBN opened at $18.15 on Thursday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE has a 1-year low of $11.70 and a 1-year high of $19.19. The company’s fifty day moving average is $15.91 and its two-hundred day moving average is $14.74. The stock has a market capitalization of $761.17 million, a price-to-earnings ratio of -19.73 and a beta of 1.17.

Institutional Trading of SI-BONE

A number of institutional investors have recently modified their holdings of SIBN. Champlain Investment Partners LLC raised its position in shares of SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after buying an additional 358,821 shares in the last quarter. American Century Companies Inc. increased its position in shares of SI-BONE by 11.0% during the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company’s stock valued at $33,341,000 after buying an additional 236,167 shares during the period. Silvercrest Asset Management Group LLC raised its position in shares of SI-BONE by 21.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company’s stock worth $27,392,000 after acquiring an additional 350,970 shares in the last quarter. Bellevue Group AG lifted its position in SI-BONE by 4.1% during the third quarter. Bellevue Group AG now owns 1,444,109 shares of the company’s stock valued at $20,189,000 after buying an additional 56,500 shares during the period. Finally, Paradigm Capital Management Inc. NY boosted its stake in SI-BONE by 5.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company’s stock worth $19,432,000 after acquiring an additional 69,831 shares in the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Anshul Maheshwari sold 5,304 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the sale, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. This trade represents a 2.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Anthony J. Recupero sold 3,670 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the sale, the insider now directly owns 222,814 shares in the company, valued at approximately $3,097,114.60. This represents a 1.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,311 shares of company stock worth $130,356 over the last three months. Corporate insiders own 3.90% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.